• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 29, 2015

View Archived Issues

Hikma buys Boehringer Ingelheim's U.S. generics business for $2.65B

LONDON – Another day, another shake-up in the generics world, with Hikma Pharmaceuticals plc agreeing to pay $2.65 billion for Boehringer Ingelheim GmbH's U.S. generics business Roxane Laboratories Inc. Read More

Sanofi strikes $2.2B immuno-oncology pact with Regeneron

Sanofi SA has pledged to invest up to $2.2 billion in a new collaboration with Regeneron Pharmaceuticals Inc. in which the longtime partners will jointly develop and commercialize the programmed cell death protein-1 (PD-1) inhibitor REGN-2810 and other new immuno-oncology antibodies. Read More

Immunomedics shares fall on epratuzumab phase III miss in lupus

DUBLIN – Epratuzumab, the anti-CD22 antibody UCB SA in-licensed from Immunomedics Inc., is a bust in systemic lupus erythematosus (SLE). Read More

Merck peers into its immuno-oncology future, likes what it sees in Ccam

Merck & Co. Inc. turned to a small Israeli biotech, Ccam Biotherapeutics Ltd., to pad its immuno-oncology (I-O) pipeline with a next-generation monoclonal antibody (MAb) targeting the immune checkpoint protein known as carcinoembryonic antigen-related cell adhesion molecule 1, or CEACAM1. Read More

Nantkwest IPO blessed: $207M for natural killers in Street's record thriller

The robust health care sector along with an investor passion for immuno-oncology helped Nantkwest Inc. to its $207 million IPO, selling 8.3 million shares at $25 each, above the targeted $20 to $23 price range and 1.3 million more shares than planned. Read More

Studies link stress, depression, microbiome

Two studies reported new links between the gut and the brain, describing new interrelationships among early life stress, depression and the microbiome. Read More

No 'duh': Obvious answer to drug R&D is not so easy to implement

The answer to reducing the cost and time of developing drugs for unmet needs seems pretty obvious – a better understanding of the disease, the patient and the molecule being developed. Read More

Financings

Cara Therapeutics Inc., of Shelton, Conn., has commenced an underwritten public offering of shares of its common stock of up to $65 million, granting the underwriters a 30-day option to purchase an additional 15 percent of the number of shares sold on the same terms and conditions. Stifel and Piper Jaffray & Co. are acting as joint book-running managers for the proposed offering. Read More

Stock movers

Read More

Other news to note

Georg-August-University Göttingen (UMG) and MRC Technology (MRCT), of London, signed an exclusive license to develop a therapy for neurodegenerative diseases based on antibody-targeting amyloid beta peptides. Read More

Earnings

United Therapeutics Corp., of Silver Spring, Md., reported second quarter revenues of $347.2 million for net income of $99.2 million, or $1.91 per diluted share. Read More

In the clinic

Fibrogen Inc., of San Francisco, said the FDA cleared the firm to proceed with a phase II study of FG-3019, a fully human monoclonal antibody designed to inhibit the activity of connective tissue growth factor, in patients with Duchenne muscuar dystrophy. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe